RESUMEN
BACKGROUND: We report a case of a patient with recurrent severe hypoglycemia after initiating the drug rasagiline (Azilect) for Parkinson disease. CASE PRESENTATION: A 25-year-old Emirati woman who had been diagnosed with Parkinson disease due to a genetic mutation since the age of 18 years presented to our hospital. She had been treated with a rotigotine patch 2 mg per day along with carbidopa + levodopa + entacapone 25 mg/100 mg/200 mg (Stalevo) over these years. Recently, her Stalevo had been changed to rasagiline (a monoamine oxidase B inhibitor). Soon after this change, she started experiencing recurrent documented severe hypoglycemia requiring hospitalization. Her hypoglycemic symptoms completely disappeared after 5-7 days of drug withdrawal. Despite detailed evaluation, no other causal relationship was documented except for rasagiline. CONCLUSIONS: To the best of our knowledge, this case report documents an unknown association between rasagiline and hypoglycemia.
Asunto(s)
Hipoglucemia/inducido químicamente , Indanos/efectos adversos , Inhibidores de la Monoaminooxidasa/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Adulto , Femenino , HumanosRESUMEN
A series of substituted (pyridin-4-yl)phenyl-2-methoxybenzamide and their derivatives were prepared and screened for their anti-inflammatory activities. Initially the acute toxicity of the compounds was assayed via the determination of their LD50. Some of the newly synthesized compounds exhibited better pharmacological and biological responses than the reference controls with low concentrations. The structures of newly synthesized compounds were confirmed by chemical, elemental and spectroscopic evidences.
Asunto(s)
Antiinflamatorios no Esteroideos , Benzamidas , Animales , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacología , Benzamidas/síntesis química , Benzamidas/química , Benzamidas/farmacología , Masculino , Estructura Molecular , RatasRESUMEN
In continuation of our previous work, fused steroidal derivatives with pyrane, pyridine, pyrimidine moieties were synthesized and evaluated as androgenic-anabolic agents. Some of the newly synthesized compounds are exhibited pronounced androgenic-anabolic activities.